SLGL on Nasdaq
Sol-Gel Technologies Ltd.
Pharmaceutical preparations company, listed on Nasdaq (SLGL). Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with Evofem Biosciences, Inc., SCYNEXIS INC or CASI Pharmaceuticals, Inc., or pick any stock.
- TickerSLGL on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersL31
- Incorporated inIsrael3
- Business address7 Golda Meir St., Weizmann Science Park, Ness Ziona, 74036483
- Filer categoryNon-accelerated filer3
See how the biggest companies compare on our leaderboards
2024 and 2025 were approximately $134, $2 and $47, respectively. Our current capital expenditure involves equipment and leasehold improvements.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-38.9%Operating margin2
-31.6%Net margin2
68.0%Revenue growth, 20252
-26.9%Return on equity2
$275.0KFree cash flow2
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
License brought in 96% of the revenue Sol-Gel Technologies Ltd. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| License | $380.0K | $9.8M | $18.6M |
| Royalty | $1.2M | $1.6M | $707.0K |
| Service, Other | $0 | $126.0K | $82.0K |
Regions
United States brought in 86% of the revenue Sol-Gel Technologies Ltd. broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $0 | $0 | $16.7M |
| CA [member] | $380.0K | $681.0K | $1.7M |
| Switzerland | $1.0M | $1.5M | $711.0K |
| Segment Geographical Groups Of Countries Group Five | $147.0K | $691.0K | $278.0K |
| [Canada] | $0 | $4.9M | $27.0K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development100¢$22.8M
Out of $19.4M in revenue.2 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending15¢$47.0K
- Kept or used elsewhere85¢$275.0K
Out of $322.0K of cash from operations.2
Financial statements
No quarterly figures reported.
Every line of the income statement as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| REVENUES | $19.4M | $11.5M | $1.6M |
| Research and development expenses | $22.8M | $17.8M | $23.5M |
| GENERAL AND ADMINISTRATIVE EXPENSES | $4.2M | $5.7M | $7.4M |
| OTHER INCOME, net | $54.0K | $0 | $55.0K |
| TOTAL OPERATING LOSS | -$7.5M | -$12.0M | -$29.3M |
| FINANCIAL INCOME, net | $1.4M | $1.4M | $2.1M |
| NET LOSS FOR THE YEAR | -$6.1M | -$10.6M | -$27.2M |
| BASIC LOSS PER ORDINARY SHARE | -$2.19 | -$3.79 | -$10.01 |
| DILUTED LOSS PER ORDINARY SHARE | -$2.19 | -$3.79 | -$10.01 |
| WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC LOSS PER SHARE | 2.8M shares | 2.8M shares | 2.7M shares |
| WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF DILUTED LOSS PER SHARE | 2.8M shares | 2.8M shares | 2.7M shares |
No quarter-by-quarter statement was filed.
No quarterly figures reported.
Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 6 quarters (quarterly), latest first.2
| Period ending | 2025-12-31 | 2025-04-30 | 2025-03-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $11.0M | $19.5M | $7.5M | ||
| Bank deposits | $0 | $12.0K | |||
| Marketable securities | $13.0M | $4.4M | $20.5M | ||
| Accounts receivables | $2.0M | $3.6M | |||
| Prepaid expenses and other current assets | $1.0M | $3.8M | |||
| TOTAL CURRENT ASSETS | $27.0M | $31.3M | |||
| Restricted long-term deposits and cash equivalents | $1.3M | $1.3M | |||
| Long-term receivables | $0 | $1.0M | |||
| Property and equipment, net | $140.0K | $202.0K | |||
| Operating lease right-of-use assets | $1.0M | $1.4M | |||
| Other long-term assets | $62.0K | $13.0K | |||
| Funds in respect of employee rights upon retirement | $393.0K | $595.0K | |||
| TOTAL NON-CURRENT ASSETS | $2.9M | $4.6M | |||
| TOTAL ASSETS | $29.9M | $35.8M | |||
| Accounts payable | $735.0K | $1.3M | |||
| Other accounts payable | $4.9M | $3.6M | |||
| Current maturities of operating leases | $495.0K | $430.0K | |||
| TOTAL CURRENT LIABILITIES | $6.2M | $5.3M | |||
| Operating leases liabilities | $496.0K | $878.0K | |||
| Liability for employee rights upon retirement | $439.0K | $833.0K | |||
| TOTAL LONG-TERM LIABILITIES | $935.0K | $1.7M | |||
| TOTAL LIABILITIES | $7.1M | $7.0M | |||
| Ordinary shares, NIS 1 par value authorized: 5,000,000 as of December 31, 2024 and 2025; issued and outstanding: 2,785,787 and 2,786,158 as of December 31, 2024 and December 31, 2025, respectively *. | $774.0K | $774.0K | |||
| Additional paid-in capital | $259.0M | $259.0M | |||
| Accumulated deficit | -$237.0M | -$230.9M | |||
| TOTAL SHAREHOLDERS' EQUITY | $22.8M | $28.9M | $38.6M | ||
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $29.9M | $35.8M | |||
| Common Stock, Par or Stated Value Per Share | 1.00 ILS | 1.00 ILS | 0.10 ILS | 1.00 ILS | |
| Ordinary shares, shares authorized | 5.0M shares | 5.0M shares | 50.0M shares | 5.0M shares | |
| Common Stock, Shares, Issued | 2.8M shares | 2.8M shares | |||
| Ordinary shares, shares outstanding | 2.8M shares | 2.8M shares |
| Period ending | 2025-12-31 | 2025-04-30 | 2025-03-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | $11.0M | $19.5M | $7.5M | |||
| Bank deposits | $0 | $12.0K | ||||
| Marketable securities | $13.0M | $4.4M | $20.5M | |||
| Accounts receivables | $2.0M | $3.6M | ||||
| Prepaid expenses and other current assets | $1.0M | $3.8M | ||||
| TOTAL CURRENT ASSETS | $27.0M | $31.3M | ||||
| Restricted long-term deposits and cash equivalents | $1.3M | $1.3M | ||||
| Long-term receivables | $0 | $1.0M | ||||
| Property and equipment, net | $140.0K | $202.0K | ||||
| Operating lease right-of-use assets | $1.0M | $1.4M | ||||
| Other long-term assets | $62.0K | $13.0K | ||||
| Funds in respect of employee rights upon retirement | $393.0K | $595.0K | ||||
| TOTAL NON-CURRENT ASSETS | $2.9M | $4.6M | ||||
| TOTAL ASSETS | $29.9M | $35.8M | ||||
| Accounts payable | $735.0K | $1.3M | ||||
| Other accounts payable | $4.9M | $3.6M | ||||
| Current maturities of operating leases | $495.0K | $430.0K | ||||
| TOTAL CURRENT LIABILITIES | $6.2M | $5.3M | ||||
| Operating leases liabilities | $496.0K | $878.0K | ||||
| Liability for employee rights upon retirement | $439.0K | $833.0K | ||||
| TOTAL LONG-TERM LIABILITIES | $935.0K | $1.7M | ||||
| TOTAL LIABILITIES | $7.1M | $7.0M | ||||
| Ordinary shares, NIS 1 par value authorized: 5,000,000 as of December 31, 2024 and 2025; issued and outstanding: 2,785,787 and 2,786,158 as of December 31, 2024 and December 31, 2025, respectively *. | $774.0K | $774.0K | ||||
| Additional paid-in capital | $259.0M | $259.0M | ||||
| Accumulated deficit | -$237.0M | -$230.9M | ||||
| TOTAL SHAREHOLDERS' EQUITY | $22.8M | $28.9M | $38.6M | $42.2M | ||
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $29.9M | $35.8M | ||||
| Common Stock, Par or Stated Value Per Share | 1.00 ILS | 1.00 ILS | 0.10 ILS | 1.00 ILS | ||
| Ordinary shares, shares authorized | 5.0M shares | 5.0M shares | 50.0M shares | 5.0M shares | ||
| Common Stock, Shares, Issued | 2.8M shares | 2.8M shares | ||||
| Ordinary shares, shares outstanding | 2.8M shares | 2.8M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss for the year | -$6.1M | -$10.6M | -$27.2M |
| Depreciation | $109.0K | $233.0K | $342.0K |
| Gain from disposal of property and equipment | -$54.0K | -$4.0K | -$55.0K |
| Changes in accrued liability for employee rights upon retirement, net | -$192.0K | -$51.0K | $6.0K |
| Share-based compensation expenses | $82.0K | $786.0K | $1.9M |
| Net changes in operating leases | $82.0K | -$50.0K | $35.0K |
| Changes in fair value of marketable securities | $26.0K | $175.0K | -$436.0K |
| Financial expenses, net | $204.0K | $4.0K | $89.0K |
| Receivables from collaborative and licensing arrangements | $0 | $0 | $7.9M |
| Accounts receivables | $1.6M | -$3.2M | -$315.0K |
| Prepaid expenses and other current assets | $2.8M | -$981.0K | -$1.3M |
| Long-term receivables and other long-term assets | $976.0K | -$983.0K | $0 |
| Accounts payable and other | $820.0K | $780.0K | $1.5M |
| Net cash provided by (used in) operating activities | $322.0K | -$13.9M | -$17.7M |
| Purchase of property and equipment | -$47.0K | -$2.0K | -$134.0K |
| Proceeds from sale of property and equipment | $54.0K | $6.0K | $74.0K |
| Short-term deposits | $12.0K | $10.0M | $2.5M |
| Long-term deposits | -$32.0K | $817.0K | -$813.0K |
| Investments in marketable securities | -$14.1M | $0 | -$23.2M |
| Proceeds from sale and maturity of marketable securities | $5.5M | $15.9M | $11.8M |
| Net cash provided by (used in) investing activities | -$8.6M | $26.7M | -$9.7M |
| Proceeds from exercise of options | $6.0K | $0 | $268.0K |
| Proceeds from issuance of shares and warrants through placement from the controlling shareholder | $0 | $0 | $10.0M |
| Proceeds from issuance of shares and warrants through public offering, net of issuance costs | $0 | $0 | $11.5M |
| Net cash provided by financing activities | $6.0K | $0 | $21.8M |
| EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS | -$188.0K | -$1.0K | -$73.0K |
| INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH EQUIVALENTS | -$8.4M | $12.8M | -$5.7M |
| Recognition of new operating lease ROU and liabilities | $0 | $127.0K | $1.6M |
| Interest received | $654.0K | $1.6M | $1.3M |
No quarter-by-quarter statement was filed.
Leadership
Who has led Sol-Gel Technologies Ltd., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chair
Chief financial officer
Chief operating officer
- Chief executive officerMoshe Arkin Mar 18, 2026 to now11
- ChairMoshe Arkin Mar 18, 2026 to now11
- Chief financial officerEyal Ben-Or Mar 18, 2026 to now12
- Chief operating officerItzik Yosef Mar 18, 2026 to now13
Board members and other officers (8)
- Chief Business OfficerMichael Glezin Mar 18, 2026 to now14
- VP Research & Dev.Ofer Toledano Mar 18, 2026 to now15
- VP Clinical, Reg & QualityOfra Levy-Hacham Mar 18, 2026 to now16
- Board memberHanna Lerman Mar 18, 2026 to now17
- Board memberItai Gidon Arkin Mar 18, 2026 to now18
- Board memberRan Gottfried Mar 18, 2026 to now19
- Board memberSharon Kochan Mar 18, 2026 to now20
- Board memberYuval Yanai Mar 18, 2026 to now21
Timeline
- Mar 18, 2026New chief executive Moshe Arkin becomes CEO11
Filings
185 filings to the SEC since October 2021: 6 annual reports, 37 insider forms, 23 large holders, 119 other. The latest 20:
- Oct 6, 20266-K EDGAR
- Sep 30, 20266-K EDGAR
- Sep 17, 20266-K EDGAR
- Sep 14, 20264 EDGAR
- Sep 9, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Aug 31, 20264 EDGAR
- Aug 20, 20266-K EDGAR
- Aug 14, 20264 EDGAR
- Jul 15, 20264 EDGAR
- Jul 10, 20264 EDGAR
- Jul 2, 20264 EDGAR
- Jun 9, 2026SCHEDULE 13G/A EDGAR
- May 28, 20266-K EDGAR
- May 22, 20264 EDGAR
- May 14, 20264 EDGAR
- May 6, 2026SCHEDULE 13G/A EDGAR
- Apr 15, 2026SCHEDULE 13D/A EDGAR
- Mar 31, 2026SCHEDULE 13G EDGAR
- Mar 24, 20264 EDGAR
The 185 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
43 open-market trades by officers, directors and large owners since October 2021: 43 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | Opaleye Management Inc.10% owner | Buy | 1,493 | $65.95 | $98.5K | Form 4 |
| Sep 10, 2026 | Opaleye Management Inc.10% owner | Buy | 1,631 | $66.80 | $109.0K | Form 4 |
| Sep 9, 2026 | Opaleye Management Inc.10% owner | Buy | 3,097 | $68.71 | $212.8K | Form 4 |
| Sep 8, 2026 | Opaleye Management Inc.10% owner | Buy | 3,861 | $68.82 | $265.7K | Form 4 |
| Sep 4, 2026 | Opaleye Management Inc.10% owner | Buy | 3,018 | $69.14 | $208.7K | Form 4 |
| Sep 2, 2026 | Opaleye Management Inc.10% owner | Buy | 900 | $68.95 | $62.1K | Form 4 |
| Sep 1, 2026 | Opaleye Management Inc.10% owner | Buy | 783 | $69.52 | $54.4K | Form 4 |
| Aug 31, 2026 | Opaleye Management Inc.10% owner | Buy | 5,217 | $68.28 | $356.2K | Form 4 |
| Aug 28, 2026 | Opaleye Management Inc.10% owner | Buy | 35,113 | $69.32 | $2.4M | Form 4 |
| Aug 12, 2026 | Opaleye Management Inc.10% owner | Buy | 951 | $71.50 | $68.0K | Form 4 |
| Jul 14, 2026 | Opaleye Management Inc.10% owner | Buy | 920 | $73.43 | $67.6K | Form 4 |
| Jul 13, 2026 | Opaleye Management Inc.10% owner | Buy | 775 | $73.89 | $57.3K | Form 4 |
| Jul 10, 2026 | Opaleye Management Inc.10% owner | Buy | 229 | $73.95 | $16.9K | Form 4 |
| Jul 8, 2026 | Opaleye Management Inc.10% owner | Buy | 300 | $73.69 | $22.1K | Form 4 |
| Jul 2, 2026 | Opaleye Management Inc.10% owner | Buy | 1,400 | $71.97 | $100.8K | Form 4 |
| Jul 1, 2026 | Opaleye Management Inc.10% owner | Buy | 312 | $71.99 | $22.5K | Form 4 |
| May 20, 2026 | Opaleye Management Inc.10% owner | Buy | 1,563 | $64.43 | $100.7K | Form 4 |
| May 13, 2026 | Opaleye Management Inc.10% owner | Buy | 1,937 | $66.87 | $129.5K | Form 4 |
| May 12, 2026 | Opaleye Management Inc.10% owner | Buy | 1,500 | $67.98 | $102.0K | Form 4 |
| Mar 24, 2026 | Opaleye Management Inc.10% owner | Buy | 39,665 | $72.00 | $2.9M | Form 4 |
All 43 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Phoenix Financial Ltd.SCHEDULE 13G/A, 5 filings Feb 7, 2022 to Jun 9, 202622
- Opaleye Management Inc.SCHEDULE 13G/A, 5 filings Aug 29, 2025 to May 6, 202623
- Moshe ArkinSCHEDULE 13D/A, 5 filings Mar 20, 2023 to Apr 15, 202624
- GREAT POINT PARTNERS LLCSCHEDULE 13G, 1 filing Mar 31, 202625
- Migdal Insurance & Financial Holdings Ltd.SCHEDULE 13G, 5 filings Feb 2, 2022 to Nov 13, 202526
- ARMISTICE CAPITAL, LLCSC 13G/A, 2 filings Feb 14, 2024 to Nov 14, 202427
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11SEC EDGARMoshe Arkin, Chief executive officer
- 12SEC EDGAREyal Ben-Or, Chief financial officer
- 13SEC EDGARItzik Yosef, Chief operating officer
- 14
- 15SEC EDGAROfer Toledano, VP Research & Dev.
- 16
- 17SEC EDGARHanna Lerman, Board member
- 18SEC EDGARItai Gidon Arkin, Board member
- 19SEC EDGARRan Gottfried, Board member
- 20SEC EDGARSharon Kochan, Board member
- 21SEC EDGARYuval Yanai, Board member
- 22
- 23
- 24
- 25
- 26
- 27